Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients

Laure Gossec,1,2 Martin Soubrier,3 Frantz Foissac,4 Anna Molto,5,6 Pascal Richette,7,8 Catherine Beauvais,9 Adeline Ruyssew-Witrand,10 Aleth Perdriger,11 Isabelle Chary-Valckenaere,12 Gael Mouterde,13 Emanuelle Dernis,14 Liana Euller-Ziegler,15 René-Marc Filpo,16 Mélanie Gilson,17 Sandrine Guis,18 Xavier Mariette,19 Sophie Pouplin,20 Thierry Marhadour,21 Thierry Schaeverbeke,22 Christelle Sordet,23 Françoise Fayet,3 Maxime Dougados5,6

ABSTRACT
Background/purpose Cardiovascular (CV) risk, cancer, infections and osteoporosis should be screened for in rheumatoid arthritis (RA). The objective was to assess 3-year effects of a nurse visit for comorbidity counselling.

Methods This was an open long-term (3 years) extension of the Comorbidities and Education in Rheumatoid Arthritis 6-month randomised controlled trial in which patients with definite, stable RA were visiting a nurse for comorbidity counselling. Comorbidity status was assessed and nurses provided advice on screening and management, at baseline and 3 years later. A score was developed to quantify comorbidity screening and management: 0–100, where lower scores indicate better screening and management. The score was compared between baseline and 3-year assessment using a Wilcoxon test for paired data.

Results Of the 970 recruited patients, 776 (80%) were followed-up at 2–4 years and 769 (79%) had available data for comorbidities at both time points: mean (±SD) age 58 (±11) years and mean disease duration 14 (±10) years; 614 (80%) were women, the mean Disease Activity Score 28 was 3.0±1.3, and 538 (70%) were receiving a biologic.

At baseline, the mean comorbidity screening score was 36.6 (±19.9) and it improved at 3 years to 24.3 (±17.8) (p<0.0001), thus with a relative improvement of 33% (improvement of 12 points). CV risk screening, vaccination status and bone densitometry performance improved the most.

Conclusions Comorbidity screening was suboptimal but improved notably over 3 years, after a nurse-led programme aiming at checking systematically for comorbidity screening and giving patient advice. This long-term efficacy pleads in favour of nurse-led interventions to better address comorbidities in RA.

Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease which, on top of the burden associated with the disease itself, is often associated with comorbidities.1–4 Indeed, in RA patients, some comorbidities are more common than in the general population.5–7
population (in particular, cardiovascular (CV), osteoporosis, infections or lymphoma), whereas some are not more frequent but appear to be less well-managed than in the general population (eg, breast cancer).5–10

Some comorbidities of particular interest in RA are CV risk factors and disease, cancer, infections and osteoporosis. Numerous studies have shown that excess mortality in RA patients is due to increased CV disease, and that both the inflammation and traditional CV risk factors, such as hyperlipidaemia or high blood pressure, are involved.5–13 Cancers are overall not more frequent in RA patients though an increase is noted for lung—chest cancers and lymphomas. Furthermore, it appears RA patients are less well screened for cancer than subjects without RA; this is the case for mammography in women.10–15 Infections are frequent in RA due to iatrogenic immunodepression.5 Finally, osteoporosis is a frequent comorbidity, and RA is considered a risk factor for osteoporosis in the FRAX risk tool endorsed by the WHO.16–18

Some of these comorbidities can be screened for or prevented. CV risk factors can be managed; cancers can be screened for; infections can in part be prevented by adequate vaccination (ie, influenza and pneumococcus) and osteoporosis can be screened for and treated.19–21 The European League Against Rheumatism (EULAR) has issued recommendations for CV risk assessment and vaccination in RA, and international recommendations for cancer and osteoporosis screening also exist.19–24 In France, national recommendations have recently been developed as well.14 However, to date, the screening and prevention of comorbidities is far from optimal in both the primary and secondary prevention.5,20,21,25–28

In 2012, we ran the COMEDRA (Comorbidities and Education in Rheumatoid Arthritis) trial.4 In this randomised controlled trial, RA patients with stable disease were randomised to an early or delayed intervention comprising a nurse-led visit to assess comorbidities and inform patients and physicians of need for intervention. The nurse did not prescribe any intervention but intervened for patient education and systematic screening. The COMEDRA trial yielded positive results, with better comorbidity screening and management in the early intervention group, at the 6 months time point.4

We were interested to explore the long-term effects of a nurse intervention (as performed in COMEDRA) on the screening and prevention of comorbidities.4 For this reason, the patients in the COMEDRA trial were followed-up in an open-label extension study of 36 months to reassess the comorbidities and the long-term utility of the initial standardised follow-up.

The objectives of this follow-up study were to (i) assess comorbidity incidence and prevalence in the COMEDRA trial, at baseline and 3 years after the trial ended and (ii) assess screening and management of selected comorbidities in this population.

PATIENTS AND METHODS

Study design
The COMEDRA initial trial was a prospective, randomised, 6-month, parallel-group, open-label trial.4 COMEDRA was a multicentre French study in 5 centres around Paris and 13 centres over the whole country; centres were tertiary care centres with a focus on RA. The trial comprised two arms (ie, comorbidity assessment and a control group, where patients were taught disease activity self-assessment) and lasted 6 months (see figure 1).

The present results are issued from an open-label long-term (3 years) extension of the COMEDRA trial.

**Figure 1** Flowchart of patient disposition in the COMEDRA trial and for the 3-year follow-up. COMEDRA, Comorbidities and Education in Rheumatoid Arthritis; M0, month 0; M6, month 6; RA, rheumatoid arthritis.
Table 1 Comorbidity screening/prevention score

| Comorbidity                           | Screening or prevention measure                                      | Optimal timing                        | Points in the score |
|--------------------------------------|-----------------------------------------------------------------------|---------------------------------------|---------------------|
| **CV disease screening (50 points)** | Diabetes: Fasting blood glucose                                      | Once per year                         | 15                  |
|                                      | High blood pressure: Blood pressure measurement                      | Once per year                         | 15                  |
|                                      | Hyperlipidaemia: Lipid measurement                                   | Once per year                         | 15                  |
|                                      | Renal insufficiency: Creatinine measurement                          | Once per year                         | 5                   |
| **Cancer screening (20 points)**     | Colon/rectum: Faecal occult blood test or colonoscopy                 | If age>50 years: every 2 (test) to 5 (colonoscopy) years | 7 men and 5 women |
|                                      | Skin: Dermatologist clinical assessment                               | Once if immunosuppressants            | 6 men and 5 women   |
|                                      | Prostate: Digital rectal examination or prostate-specific antigen dosage | If male gender and age>50 years: once | 7 men and 0 women   |
|                                      | Breast: Mammography                                                  | If female gender and age 50–75 years: every 2 years | 0 men and 5 women |
|                                      | Cervix: Cervical smear                                               | If female gender: every 3 years       | 0 men and 5 women   |
| **Infection prevention (20 points)** | Influenza: Vaccination                                               | Once per year                         | 10                  |
|                                      | Pneumococcus: Vaccination                                            | Every 5 years                         | 10                  |
| **Osteoporosis (10 points)**         | Osteoporosis: Bone mineral density                                   | Once in lifetime                      | 10                  |

The score ranges 0–100, where optimal screening and prevention is a score of 0. Points in the score were given to patients not receiving the measure and points differed for cancer between women and men. CV, cardiovascular.

Patients

Patients in COMEDRA had definite, stable RA, as explained elsewhere. Briefly, consecutive patients fulfilling the 1987 American College of Rheumatology criteria for the diagnosis of RA, aged between 18 and 80 years, with a disease considered by the treating rheumatologist to have been stable for at least 3 months, were included.429

Intervention

Comorbidity status was assessed, and nurses provided advice on screening and management, during the trial and 3 years later. A screening prescription, including blood cell count, erythrocyte sedimentation rate, C reactive protein, creatinine and vitamin D levels, lipid profile and dipstick urine protein test, was sent to each patient. The nurses were asked to (i) report the presence of comorbidities (eg, stroke); (ii) screen for risk factors (eg, hypertension for CV disease) and (iii) give patients advice on targets for screening and management (eg, need for vaccination) without prescribing the interventions. The nurse advised the patient to visit her/his general practitioner and/or rheumatologist if risk factors were detected. In parallel, a report of the screening findings was sent to the general practitioner and the rheumatologist of each patient.

Data collection

General and patient-reported data

Patient demographics and disease characteristics were collected at baseline, including previous/current RA treatments (glucocorticoids and disease-modifying drugs, synthetic and biological). The presence of rheumatoid factor and/or anticyclic citrullinated peptide, the presence of radiographic erosions and the Disease Activity Score 28 (DAS28) at inclusion were recorded. Pain and patient global assessment single questions were assessed. Function was collected using the modified Health Assessment Questionnaire.

Comorbidities

For this follow-up study, the baseline comorbidity data were issued from either the first visit (for patients randomised to the comorbidity arm) or the 6-month (second) visit (for patients randomised to the control arm) (figure 1). The follow-up comorbidity data were collected at the 3-year visit. The prevalence of comorbidities was assessed at baseline (as defined above) and incidence was assessed at the 3-year visit. This incidence corresponds to new cases over the follow-up (thus prospective incidence); it is reported for informative purposes, and should not be considered in parallel with the screening procedures. The comorbidities of interest collected here were CV risk factors (diabetes, high blood pressure, hyperlipidaemia, obesity: body mass index ≥ 30 kg/m², and current smoking) and major CV events (defined as myocardial infarct angina, stroke and obliterating arteriopathy), cancers (including colon cancer, breast cancer, lung cancer, prostate cancer,
uterus cancer, skin cancer (all types) and lymphoma) and history of fracture.

Comorbidity screening and prevention score

The following screening and prevention measures against comorbidities were considered (table 1): (i) for CV disease: blood pressure measurement, and blood tests for fasting blood glucose, lipids and serum creatinine to be performed at least once a year as per EULAR guidelines at the time of the study; (ii) for cancers: screening of colon/rectum cancer, skin cancer, and prostate (for men) or breast and cervix cancer (for women), to be performed at frequencies in accordance with international guidelines; (iii) for infectious disease prevention: agreement with the vaccination recommendations was defined as influenza vaccination performed within the last 12 months and pneumococcal vaccination performed within the last 5 years and (iv) for osteoporosis screening: bone mineral density once in lifetime.

To assess these screening and prevention measures, a comorbidity screening and prevention score was developed by the steering committee (table 1). This score quantifies comorbidity screening and management as a continuous score (range 0–100), where lower scores indicate better screening and management (ie, optimal screening and detection=0 points). The points were attributed to the four main comorbidity screening measures as explained above, taking into account the prevalence and severity of these comorbidities with the most points being given to CV disease. Given gender differences in prevalences of cancer, points for cancer detection differed between women and men (table 1). Patients not at risk (eg, demographically not at risk, such as women for prostate cancer) or people presenting already with the comorbidity (ie, considered not in need of screening/detection) were scored as 0=optimal screening.

Illustration of the score

For illustration purposes, some examples are: A score of 20–25 points could correspond to (no lipid screening and no pneumococcus vaccination), or (neither breast nor cervix cancer screening and no osteoporosis screening), with other measures properly taken. A score of 35–40 points could correspond to (no lipid screening, no pneumococcus vaccination and no diabetes screening), or (neither breast nor cervix cancer screening, no osteoporosis screening, no colon screening and no influenza vaccination).

Statistical analysis

We analysed all patients who took part in the study visit at month 36. Continuous variables are presented as means and SD and categorical variables as counts (percentage). The comorbidity screening and prevention score were compared between baseline (either study entry or month 6 visit) and 3-year assessment using a Wilcoxon-Mann-Whitney test for paired data. The prevalence of comorbidities was assessed as overall percentage of patients at baseline. The relative increase in the given comorbidity during the follow-up was also evaluated as percentage increase and as incidence per 100 patient-years. Then for each comorbidity, the proportion of patients in conformity for screening/prevention was compared between baseline and 3-year assessment using a McNemar test for paired data. Statistical analyses were performed by using ad hoc routines implemented in R V.3.3.1 software.

RESULTS

Patient disposition

Of the 970 recruited patients, 776 (80%) were followed-up at 2–4 years, between May 2014 and October 2015 (15, 1.5%, had died) and 709 (79%) had available data for comorbidities and screening at both time points. There were no notable differences between those followed-up or not (data not shown).

Patient characteristics

Patients were typical of an RA tertiary care population (table 2): mean (±SD) age 58 (±11) years and mean disease duration 14 (±10) years; 614 (80%) were women and 538 (70%) were receiving a biologic. The mean baseline and 3-year DAS28 scores were, respectively, 2.99±1.30 and 2.83±1.34.

Table 2 Characteristics of 769 patients with RA

| Characteristic                                      | Result       |
|----------------------------------------------------|--------------|
| Age, years, mean (SD)                              | 58.0 (10.8)  |
| Gender, female, N (%)                              | 614 (79.8)   |
| Disease duration, years, mean (SD)                 | 13.7 (9.8)   |
| Rheumatoid factor or anticyclic citrullinated peptide positivity, N (%) | 651 (84.7)   |
| Presence of radiographic erosions, N (%)           | 566 (73.8)   |
| DAS28 ESR, mean (SD)                               | 2.99 (1.30)  |
| Swollen joint count (0–28), mean (SD)              | 2.0 (2.9)    |
| Pain (0–10), mean (SD)                             | 3.0 (2.2)    |
| Patient global assessment (0–10), mean (SD)        | 2.9 (2.1)    |
| Modified HAQ score (0–3), mean (SD)                | 0.39 (0.52)  |
| Disease-modifying treatment over the past 3 months, N (%) | 762 (99.1)   |
| Current biologic treatment, N (%)                  | 538 (69.9)   |
| Current oral glucocorticoid treatment, N (%)       | 274 (35.7)   |
| For patients taking glucocorticoids, prednisone-equivalent dose per day, mg, mean (SD) | 5.4 (5.4)    |

Prednisone equivalent dose was calculated taking into account all intakes of glucocorticoids, including joint injections, over the last 90 days. DAS28 ESR, Disease Activity Score on 28 joints calculated with the erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis.
Table 3 Prevalence of selected risk factors and comorbidities at baseline and 3 years

| Comorbidity                  | Prevalence at baseline (month 0 for group I and month 6 for group II), N (%) | Prevalence at follow-up after 3 years, N (%) | Incidence for 100 patient-years (95% CI) (absolute incidence as %) |
|------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------|
| **Risk factors**             |                                                                                |                                               |                                                                     |
| CV risk                      |                                                                                |                                               |                                                                     |
| Diabetes                     | 39 (5.1)                                                                       | 51 (6.6)                                      | 0.6 (0.3 to 1.0) (1.6)                                               |
| High blood pressure          | 238 (30.9)                                                                     | 270 (35.1)                                    | 2.1 (1.5 to 2.9) (4.2)                                               |
| Hyperlipidaemia              | 149 (19.4)                                                                     | 170 (22.1)                                    | 1.1 (0.7 to 1.7) (2.7)                                               |
| Obesity (BMI≥30 kg/m²)       | 114 (14.8)                                                                     | 124 (16.1)                                    | 1.5 (1.0 to 2.1) (1.3)                                               |
| Smoking                      | 122 (15.9)                                                                     | 104 (13.5)                                    | 0.5 (0.2 to 0.9) (−2.3)                                              |
| **Comorbidities**            |                                                                                |                                               |                                                                     |
| MACE                         |                                                                                |                                               |                                                                     |
| Myocardial infarct           | 13 (1.7)                                                                       | 18 (2.3)                                      | 0.2 (0.1 to 0.5) (0.6)                                               |
| Angina                       | 9 (1.2)                                                                        | 17 (2.2)                                      | 0.4 (0.2 to 0.7) (1.0)                                               |
| Stroke                       | 16 (2.1)                                                                       | 29 (3.8)                                      | 0.6 (0.3 to 1.0) (1.7)                                               |
| Obliterating arteriopathy    | 8 (1.0)                                                                        | 15 (2.0)                                      | 0.3 (0.2 to 0.7) (0.9)                                               |
| Cancer                       |                                                                                |                                               |                                                                     |
| Colon                        | 2 (0.3)                                                                        | 2 (0.3)                                       | 0 (0) (0)                                                           |
| Breast                       | 23 (3.0)                                                                       | 27 (3.5)                                      | 0.2 (0.1 to 0.5) (0.5)                                               |
| Lung                         | 1 (0.1)                                                                        | 2 (0.3)                                       | 0.0 (0.0 to 0.3) (0.2)                                               |
| Prostate                     | 3 (0.4)                                                                        | 4 (0.5)                                       | 0.0 (0.0 to 0.3) (0.1)                                               |
| Uterus                       | 7 (0.9)                                                                        | 7 (0.9)                                       | 0 (0) (0)                                                           |
| Skin (all types)             | 26 (3.4)                                                                       | 36 (4.7)                                      | 0.5 (0.2 to 0.8) (1.3)                                               |
| Lymphoma                     | 2 (0.3)                                                                        | 3 (0.4)                                       | 0.0 (0.0 to 0.3) (0.1)                                               |
| Osteoporosis                 |                                                                                |                                               |                                                                     |
| Bone fracture                | 245 (31.9)                                                                     | 292 (38.2)                                    | 3.1 (2.4 to 4.2) (6.1)                                               |

BMI, body mass index; CV, cardiovascular; MACE, major CV event.

Incidence and prevalence of comorbidities
At baseline, the most frequent comorbidities (table 3) were a history of fracture (31.9%) and high blood pressure (30.9%).

At 3 years, most of the comorbidities had increased (table 3). The comorbidities those had the most increased in this population aged around 60 years were fractures (incidence 3.1 per 100 patient-years) and high blood pressure (2.1 per 100 patients-years). Among CV risk factors, hyperlipidaemia had increased the most (incidence, 1.1 per 100 patient-years), whereas smoking had decreased (2% of the population stopped smoking).

Comorbidity screening and prevention
At baseline, the mean comorbidity screening score was 36.6 (±19.9) and it has improved at 3 years to 24.3 (±17.8) (p<0.0001), thus with an absolute mean improvement of around 12 points, and a relative improvement of 33% (figure 2). The improvement for each element of the score is presented in table 4. CV risk screening, vaccination status and bone densitometry performance improved the most.

DISCUSSION
The present study brings important information on comorbidities in RA, and importantly, addresses the long-term effects of a nurse intervention to enhance screening and prevention of comorbidities. We found the most frequent comorbidities/risk factors and with the highest incidence in this population of patients with moderate-to-low disease activity and frequent intake of biologics were a history of fracture (prevalence 31.9%) and high blood pressure (prevalence 30.9%). We also developed a screening and prevention score, and found that screening and prevention was suboptimal in this population but improved after the nurse-led intervention.

This study has strengths and weaknesses. It is a large-scale study with granular information on comorbidities and screening procedures. However, some comorbidities, such as depression, were not assessed. Furthermore, we assessed in detail screening procedures, but not interventions performed on patients after these screening procedures. However, screening is a necessary step before interventions can be performed. The patients analysed here were often receiving biologic therapies.
Figure 2 Comorbidity screening and prevention score. (A) Baseline score. (B) Three years follow-up score.

This can be explained by the tertiary centre recruitment. It may, however, lead to higher comorbidity rates and to better screening, as these patients are often followed-up in a more rigorous way than other patients. The loss to follow-up rate was of 20% at 3 years, which indicates the difficulties of long-term follow-up studies in observational settings; however, patients lost to follow-up had similar characteristics as the other patients. Preventative measures, such as the ones taken in the present study, are costly; it would be interesting to perform cost–benefit analyses. Perhaps this may be performed in future studies of comorbidity screening. Finally, we report herein as the main criterion, screening measures; we also report incidence of comorbidities but it is important to keep in mind the lack of causality between the screening and the prevalence of comorbidities, both are presented in parallel but are not linked.

Comorbidities are frequent in RA and in the present study, the most frequent comorbidities were CV risk-related and fractures. CV risk is now well-recognised in RA. Osteoporosis was frequently noted in this population; of note, the nurses who collected information relating to fractures noted all fractures, whatever the cause, which may have overestimated events. However, fractures are frequent in RA and furthermore, this can be explained in part by glucocorticoid intake in RA patients.

In this study, the steering committee developed an innovative comorbidity prevention and screening score. This score does not assess the frequency of comorbidities, but rather focuses on the frequency of optimal screening/prevention. We believe that such a score will be useful to assess the quality of care in terms of comorbidity screening and prevention. Of note, however, not all screening or prevention actions are assessed in this score. For example, interventions to help with smoking cessation or weight loss are not assessed, since we found that such interventions are (i) difficult to quantify reliably and (ii) not often efficacious. Another issue with this score is that the definition of ‘optimal screening’ is subject to both the national guidelines (which may vary, eg, for cancer detection) and the changing recommendations (eg, for prostate cancer detection). In fact, in our score, we applied the EULAR CV screening recommendations of the time the study was designed, which referred to as yearly screening of CV risks, whereas now these recommendations have been revised to 5-yearly screening.

Comorbidity screening was suboptimal in the present study. The mean score at the end of the study was 24 points on a 0–100 scale, which could correspond to (no lipid screening and no pneumococcus vaccination), or (neither breast nor cervix cancer screening and no osteoporosis screening), with other measures properly taken. Screening does not always address the most frequent or severe comorbidities. Some resistance may be due to (i) poor knowledge of the constantly evolving screening procedures; (ii) painful or costly or otherwise anxiety-creating screening procedures and (iii) lack of clear responsibility for screening (should it be the general practitioner, the rheumatologist and the hospital team?). Empowering patients to be responsible for the comorbidity screening reminders should be explored.

The improvements seen over 3 years in the screening and prevention score after a nurse-led programme aiming at checking systematically for comorbidity screening and giving patients advice plead in favour of nurse-led interventions to better address comorbidities in RA. Of note, these patients were mainly on biologics and the study was performed in tertiary centres; perhaps both the patients and the health professionals were particularly aware of comorbidities.
| Screening or prevention measure | Percentage of patients in agreement with screening/management recommendation at baseline assessment | Percentage of patients in agreement with screening/management recommendation at 3-year follow-up | P value between baseline and follow-up |
|-------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------------|
| CV risk assessment            |                                                 |                                                 |                                      |
| Blood pressure measurement    | 64.0                                            | 96.2                                            | <0.0001                              |
| Fasting blood glucose measurement | 53.6                                          | 67.4                                            | <0.0001                              |
| Lipid measurement             | 49.8                                            | 65.2                                            | <0.0001                              |
| Creatinine measurement        | 77.8                                            | 94.5                                            | <0.0001                              |
| Cancer screening              |                                                 |                                                 |                                      |
| Colon/rectum                  | 50.3                                            | 49.7                                            | 0.19                                 |
| Skin                          | 57.9                                            | 79.7                                            | <0.0001                              |
| Prostate                      | 78.7                                            | 74.8                                            | 0.34                                 |
| Breast                        | 68.8                                            | 72.2                                            | 0.29                                 |
| Cervix                        | 63.8                                            | 63.4                                            | 0.94                                 |
| Vaccination                   |                                                 |                                                 |                                      |
| Influenza                     | 44.1                                            | 54.7                                            | <0.0001                              |
| Pneumococcus                  | 59.9                                            | 65.3                                            | <0.01                                |
| Osteoporosis screening        |                                                 |                                                 |                                      |
| Bone densitometry             | 74.4                                            | 88.0                                            | <0.0001                              |

The percentages are all percentage of patients in conformity with the screening/prevention guidelines (as presented in table 1), among patients at risk (eg, in the age and gender group at risk and without previous presence of the comorbidity). CV, cardiovascular.

In summary, this study strongly supports the long-term benefit of a single nurse-led programme for screening and preventing comorbidities. Further studies are required to evaluate different strategies, including the repetition over time of this nurse-led programme, to improve comorbidity screening and prevention in RA patients.

The improvements were particularly notable for CV screening and vaccinations. Influenza and pneumococcal vaccinations are recommended in all patients with RA. However, it is well known that a gap exists between recommendations and their implementation in real life. As EULAR recommendations for vaccinations are now widely disseminated, it can be hoped that these simple and effective measures will be more widely implemented. However, currently in France and in several other countries, there are important controversies around vaccinations (often relayed through social media with deleterious effects, at least in Western Europe and North America). The single observed improvement for cancer screening was the one related to skin cancer. This probably reflects the current interest in a potential higher risk of skin cancer on tumour necrosis factor inhibitors.

In spite of the improvement of the comorbidity screening and management score, the incidence of comorbidities increased over 3 years in the three domains (CV, cancers and fractures). It has not to be interpreted as the non-usefulness of the screening and detecting risk factors but it reinforces the previous data demonstrating that these four types of comorbidities are at risk in RA patients. Future studies need to evaluate if patients with a decrease of the comorbidity screening and management score will experience a lower increase rate of comorbidities over time.

Author affiliations
1Sorbonne Universite, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Paris, France
2Rheumatology, Pitie Salpetriere Hospital, AP-HP, Paris, France
3Rheumatology, Gabriel Montpied University Hospital, Clermont-Ferrand, France
4Clinical Research Unit Necker-Cochin, Assistance Publique—Hopitaux de Paris, Paris, France
5Rheumatology, Cochin Hospital, AP-HP, Paris, France
6INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cite, Paris Descartes University, Paris, France
7Rheumatology, Lariboisiere Hospital AP-HP, Paris, France
8Inserm UMR1132 Bioscar, Universite Paris Diderot, Paris, France
9Rheumatology, Sorbonne Universite and Hospital Saint-Antoine AP-HP, Paris, France
10Rheumatology, UMR 1027 Inserm, Paul Sabatier University and Purpan Hospital, Toulouse, France
11Rheumatology, South Hospital, Rennes 1 University, Rennes, France
12Rheumatology, Nancy University Hospital, Vandoeuvre les Nancy, France
13Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
14Rheumatology, Le Mans Hospital, Le Mans, France
15Rheumatology, University Hospital Pasteur 2, Nice, France
16Rheumatology, R Salengro Hospital, University of Lille, Lille, France
17Rheumatology, GREPI-CNRS, Grenoble Hospital and Université Joseph Fourier, Echirolles, France
RMD Open

11. Solheim DH, Karlson EW, Curhan GC. Cardiovascular care and patients with rheumatoid arthritis compared to the general population. *Arthritis & Rheumatism* 2012;64:3076–82.

12. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 2008;59:1690–7.

13. Boo S, Oh H, Froelicher ES, et al. Knowledge and perception of cardiovascular disease risk among patients with rheumatoid arthritis. *Plos One* 2017;12:e0176291.

14. Baghdadi LA, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. *Plos One* 2015;10:e0117952.

15. Gosses L, Baillet A, Dadoun S, et al. Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. *Joint Bone Spine* 2016;83:501–9.

16. Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Research* 2015;17.

17. Tanaka Y, Onira T, Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK–RANKL.

18. Curr Opin Pharmacol 2018;40:110–9.

19. Mazzucchelli R, Pérez Fernandez E, Crespi-Villarías N, et al. Trends in hip fracture in patients with rheumatoid arthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999–2015). TREND-AR study. RMD Open 2018;4.

20. Kanis JA, Harvey NC, Johanson H, et al. FRAX update. *Journal of Clinical Densitometry* 2017;20:360–7.

21. Baillet A, Gosses L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. *Ann Rheum Dis* 2016;75:965–73.

22. Coulson KA, Reed G, Gilliam BE, et al. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the consortium of rheumatology researchers of North America (CORRONA) registry. *JCR: Journal of Clinical Rheumatology* 2009;15:155–60.

23. McKeown E, Bykerk VP, De Leon F, et al. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the catch cohort. *Rheumatology* 2012;51:1662–9.

24. Peters MJL, Symmons DPM, Carey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Annals of the Rheumatic Diseases* 2010;69:325–31.

25. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Annals of the Rheumatic Diseases* 2011;70:414–22.

26. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017;76:17–28.

27. Primdahl J, Clausen J, Horslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. *Ann Rheum Dis* 2013;72:1771–6.

28. Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. *BMC Musculoskelet Disord* 2007;8.

29. Feuchtenberger M, Kleinert S, Schwab S, et al. Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. *Rheumatol Int* 2012;32:1533–9.

30. Desai SP, Lu B, Szent-Gyorgyi LE, et al. Increasing pneumococcal Vaccination for immunosuppressed patients: a cluster quality improvement trial. *Arthritis & Rheumatism* 2013;65:39–47.

31. Radner H, Neogi T, Smolen JS, et al. Performance of the 2010 ACR/EULAR recommendations for cardiovascular risk management in patients with rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis* 2014;73:114–23.

32. Prevoa MILL, Van T Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis & Rheumatism* 1995;38:44–8.

33. Cahill K, Lindson-Hawley N, Thomas KA, et al. NMD receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev* 2016;159.
32. Hider SL, Bucknall M, Cooke K, et al. The include study: integrating and improving care for patients with inflammatory rheumatological disorders in the community; identifying multimorbidity: protocol for a pilot randomized controlled trial. *Journal of Comorbidity* 2018;8.

33. Sathianathen NJ, Konety BR, Crook J, et al. Landmarks in prostate cancer. *Nat Rev Urol* 2018;15:627–42.

34. Bragazzi NL, Watad A, Amital H, et al. Debate on vaccines and autoimmunity: do not attack the author, yet discuss it methodologically. *Vaccine* 2017;35:5522–6.

35. Jang SM, Mckeever BW, Mckeever R, et al. From social media to mainstream news: the information flow of the Vaccine-Autism controversy in the US, Canada, and the UK. *Health Communication* 2019;34:110–7.

36. Raaschou P, Simard JF, Asker Hagelberg C, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. *BMJ* 2016;352.

37. Caporali R, Crepaldi G, Codullo V, et al. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? *Rheumatology* 2018;57(57 Suppl 7):vii5–10. 57.